# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Vincent van Gogh (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI010-SYN
- Date: 2026-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Elise Verhoeven, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review with the 12-week metabolic check. **S**

## History of present illness

Mr. van Gogh returns three months after his first visit, fifteen weeks after aripiprazole was started in hospital, fasting for his blood tests. He has had no voices, suspiciousness, or confusion since the six-week visit. He takes aripiprazole 10 mg and naltrexone every morning. He sleeps about seven hours and goes to bed by midnight; he noticed once that after a late night of work he felt a rush of ideas the next day, and he went to bed early as his plan says. He paints most days, outdoors now that spring has come, and has sold two paintings. He drinks one glass of wine with dinner on most days and none on two days a week. His appetite is a little greater than before. His mood is steady; he has not had thoughts of suicide or self-harm. **S**

| Element | Detail |
|---|---|
| Psychotic symptoms | None since the six-week visit |
| Early warning signs | One day of racing ideas after a late night; managed with sleep |
| Sleep | About seven hours at regular times |
| Alcohol | One glass of wine with dinner on most days; two alcohol-free days a week |
| Mood | Steady; PHQ-9 6; item 9 scored 0 |
| Weight | Appetite slightly greater; weight up 1.7 kg since intake |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Appetite a little greater; weight up 1.7 kg |
| Endocrine | Negative | No thirst or frequent urination |
| Neurological | Negative | No restlessness, stiffness, tremor, or seizures |
| Psychiatric | Negative | No voices or suspiciousness; mood steady; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Naltrexone 50 mg oral tablet, one tablet by mouth once daily **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) **S**
- Aripiprazole 10 mg oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 65.7 kg; BMI 22.7 kg/m². All vital signs are synthetic.

Fasting glucose: 94 mg/dL; Hemoglobin A1c: 5.4%; Total cholesterol: 191 mg/dL; LDL cholesterol: 112 mg/dL; HDL cholesterol: 50 mg/dL; Triglycerides: 142 mg/dL; AST: 33 U/L; ALT: 31 U/L; GGT: 49 U/L; Phosphatidylethanol (PEth): 46 ng/mL (high); PHQ-9: 6. All results are synthetic.

## Change since baseline

- Fasting glucose: 91 mg/dL at baseline, 94 mg/dL at this visit **S**
- Hemoglobin A1c: 5.3% at baseline, 5.4% at this visit **S**
- Total cholesterol: 184 mg/dL at baseline, 191 mg/dL at this visit **S**
- LDL cholesterol: 106 mg/dL at baseline, 112 mg/dL at this visit **S**
- HDL cholesterol: 52 mg/dL at baseline, 50 mg/dL at this visit **S**
- Triglycerides: 130 mg/dL at baseline, 142 mg/dL at this visit **S**
- AST: 58 U/L (high) at baseline, 33 U/L at this visit **S**
- ALT: 44 U/L at baseline, 31 U/L at this visit **S**
- GGT: 96 U/L (high) at baseline, 49 U/L at this visit **S**
- Phosphatidylethanol (PEth): 284 ng/mL (high) at baseline, 46 ng/mL (high) at this visit **S**
- PHQ-9: 13 at baseline, 6 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 65.7 kg, BMI 22.7; waist 87 cm; blood pressure 122/78, pulse 74 |
| Neurological | No akathisia, rigidity, tremor, or abnormal movements |
| Psychiatric | Euthymic; organized; no psychotic features; speech normal in rate |

All examination findings are synthetic. **S**

## Assessment and plan

1. **First episode of psychosis with mood features, provisional diagnosis, in remission** (F29). Remission for about two months. The day of racing ideas after a late night was an early warning sign that he managed well; it did not progress. The 12-week metabolic check is normal: fasting glucose 94 mg/dL, A1c 5.4%, total cholesterol 191, LDL 112, HDL 50 and triglycerides 142 mg/dL; weight up 2.7%, below the 5% that would call for action. Antipsychotic treatment continues after a first episode; the length of treatment will be decided with him later in the year. Safety reviewed: no thoughts of suicide or self-harm; the safety plan is current. **S**
   - Continue aripiprazole 10 mg daily.
   - Keep to the sleep plan and call the team after two short nights or more racing ideas.
   - Yearly glucose, A1c and lipids from now.
2. **Alcohol use disorder on naltrexone** (F10.20). PEth down to 46 ng/mL; AST 33, ALT 31 and GGT 49 U/L, now normal. **S**
   - Continue naltrexone and thiamine.
   - Liver tests and PEth at six months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg; full adherence; in remission |
| Survey | Psychotic and mood symptoms, and early warning signs | Every visit | Completed today | No psychotic symptoms; one day of racing ideas after a late night, managed with sleep |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | None |
| Examination | Weight and BMI | Every visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 65.7 kg (BMI 22.7), up 2.7% from intake. Taken at 15 weeks rather than the CMID's 12, within the APA's four months |
| Examination | Waist circumference | Baseline, then yearly | Completed today | 87 cm |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 122/78 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Completed today | Fasting glucose 94 mg/dL; A1c 5.4%; yearly from now |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Completed today | Total cholesterol 191, LDL 112, HDL 50, triglycerides 142 mg/dL; yearly from now |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Deferred | PHQ-9 6 today, item 9 scored 0. No PHQ-9 was taken in the seven weeks since the six-week visit, longer than the monthly measure advised during acute treatment, because no visit fell in that time. No harm resulted: the score fell from 8 to 6 and the care coordinator saw him weekly. Corrective action: the care coordinator now gives the PHQ-9 monthly between visits |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; no firearm access |
| Self-management | Sleep | Every visit | Completed today | About seven hours; in bed by midnight |
| Survey | Drinking (AUDIT-C and PEth) | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 46 ng/mL |
| Medication safety | Naltrexone: liver tests and opioid exposure | Liver tests before starting, then at 1 to 3 months and every 6 to 12 months | Completed today | AST 33, ALT 31, GGT 49 U/L, normal |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine daily |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Therapist every two weeks; peer specialist monthly; supported work plan: selling his paintings again |

## Goal progress

- No return of psychotic symptoms and no readmission through six months, on the lowest effective antipsychotic dose. In progress; target 2026-07-20. **S**
- PHQ-9 score below 5 by six months. In progress; target 2026-07-20. **S**
- Reduce drinking to PEth below 20 ng/mL by six months. In progress; target 2026-07-20. **S**
- Weight gain under 5% and normal glucose, A1c and lipids at the 12-week check. Outcome by 2026-04-20: Weight 65.7 kg from 64.0 (2.7%); fasting glucose 94 mg/dL, A1c 5.4%, lipids normal. **S**
- Sleep about seven hours on most nights with regular times by three months. Outcome by 2026-04-20: Seven hours on most nights, in bed by midnight. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Preventive visit in eight weeks. Six-month review with the AIMS, PEth, liver tests, and blood count. Care coordinator monthly, with the PHQ-9. **S**
- Next scheduled visit 2026-06-15: periodic adult preventive visit. **S**
